Goodbody Health Announces Opening of First Clinic in Canada
VANCOUVER, BC / ACCESSWIRE / February 18, 2022 / Goodbody Health Inc. (CSE:GDBY) (Goodbody Health" or the "Company") is pleased...
Month: February 2022
Jupiter Wellness Completes Enrollment in Double-Blind Placebo-Controlled Clinical Trial of JW-200 for the Treatment of Actinic Keratosis
Data expected Q1 2022 on efficacy of JW-200 to clear AK lesions, a common form of pre-cancerous growth that left...
Moderna Expands Its mRNA Pipeline with Three New Development Programs
mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV)mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce...
PatchMD Releases 5 New Special Formulations
Las Vegas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- PatchMD, a health and wellness service specializing in vitamin and mineral supplement...
Teladoc Health to Participate in Upcoming Investor Conferences
PURCHASE, NY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care,...
Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference
CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies...
American Cannabis Company, Inc. Provides Overall Update on Company Progress and Plans for 2022
DENVER, CO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC” or “Company”),...
Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022
SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development...
Clinical Genomics Announces New Publication from Flinders Medical Centre, Highlighting the Use of COLVERA® as a Quantitative ctDNA Biomarker for Response to Colorectal Cancer Therapy
-- Article outlines advantages and provides further data to support the use of COLVERA for assessing response to treatment and...
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased...
Acerus Announces Amendment to Loan Facilities
Pays off SWK Facility; Reduces Interest Going ForwardTORONTO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or...
Eve & Co Announces Closing of Shares for Debt Transaction
STRATHROY, Ontario, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE;...
Dante Labs Partnering with The Renato Dulbecco Foundation to advance personalized medicines for cancer, COVID-19 and rare diseases
NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, today announced...
Cronos Group Reports 2021 Third Quarter Results
Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies...
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA),...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021 The press release published yesterday at 08.00 CET...
Coloplast A/S – Announcement no. 03/2022 – Share Buyback Programme
Coloplast A/S (“Coloplast” or the “Company”) is initiating a share buyback programme totalling up to DKK 500 million, as announced...
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
ORION CORPORATION PRESS RELEASE 18...
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can...